Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elevate-CKD
NCT07753993Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Primary completion
- Oct 2030
- Countries
- 37
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Elecoglipron with Placebo (2 arms). Primary endpoint: Composite of >= 50% sustained decline in eGFR, ESKD, or all-cause mortality up to 4.5 years. Started Aug 2026; status: recruiting.
02
Drugs
elecoglipron
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07753993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07753993.